肝硬度检测用于MASLD患者HCC风险分层
该回顾性队列研究纳入30414例接受瞬时弹性成像的MASLD患者,随访69974人年,发现LSM每增加5 kPa,HCC风险增加18%(sHR 1.18,95%CI 1.14-1.21)。在无肝硬化、无临床显著门脉高压、合并糖尿病且LSM≥10 kPa的患者中,HCC年发生率为0.46/100人年(0.29-0.78),高于既往描述的HCC监测成本效益阈值。
要点
- LSM每增加5 kPa,MASLD患者HCC风险增加18%。
- 无肝硬化、糖尿病且LSM≥10 kPa者HCC年发生率0.46/100人年。
- 此类患者应考虑进行HCC监测。
核心结论
- LSM与MASLD患者HCC风险相关,非肝硬化合并糖尿病且LSM≥10 kPa者应考虑HCC监测。
研究设计与样本
- 回顾性研究,纳入VALID队列中2014年5月27日至2023年6月1日接受瞬时弹性成像的MASLD患者30414例,随访69974人年。
主要发现
- LSM每增加5 kPa,HCC风险增加18%(sHR 1.18,95%CI 1.14-1.21)。
- LSM 10-14.9、15-19.9、20-24.9和≥25 kPa的HCC年发生率分别为0.34、0.45、0.78和0.94/100人年。
- 无肝硬化、无临床显著门脉高压、合并糖尿病且LSM≥10 kPa者HCC年发生率为0.46/100人年(0.29-0.78)。
关键数值与推荐
- LSM 10-14.9 kPa:HCC年发生率0.34/100人年(95%CI 0.24-0.49)。
- LSM 15-19.9 kPa:HCC年发生率0.45/100人年(95%CI 0.27-0.76)。
- LSM 20-24.9 kPa:HCC年发生率0.78/100人年(95%CI 0.50-1.20)。
- LSM≥25 kPa:HCC年发生率0.94/100人年(95%CI 0.68-1.29)。
- 无肝硬化、无临床显著门脉高压、糖尿病且LSM≥10 kPa:HCC年发生率0.46/100人年(95%CI 0.29-0.78),高于既往HCC监测成本效益阈值。
临床怎么用
- 对MASLD患者可依据LSM进行HCC风险分层。
- 非肝硬化MASLD合并糖尿病且LSM≥10 kPa者应考虑HCC监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the fastest-rising cause of HCC. A third of MASLD-HCC occur in the absence of cirrhosis, but tools to predict MASLD-HCC are lacking. Our study aimed to examine whether liver stiffness measurement (LSM) is associated with HCC risk in MASLD, identify if LSM thresholds can predict HCC risk, and identify patients for cost-effective HCC surveillance. APPROACH AND RESULTS: We conducted a retrospective study of the Veterans Analysis of Liver Disease (VALID) cohort and included patients with MASLD who underwent transient elastography between May 27, 2014, and June 1, 2023. HCC incidence rates were calculated, and we fit multivariable Cox proportional models to study the association of LSM with HCC risk. Among 30,414 participants with MASLD followed over 69,974 person-years (PY), HCC risk increased by 18% with every 5 kPa increase in LSM (subdistribution hazard ratio: 1.18, 95% CI: 1.14-1.21). The annual incidence of HCC per 100 PY was 0.34 (0.24-0.49) with LSM 10-14.9, 0.45 (0.27-0.76) with LSM 15-19.9, 0.78 (0.50-1.20) for LSM 20-24.9, and 0.94 (0.68-1.29) per 100 PY with LSM ≥25 kPa. In patients with MASLD without cirrhosis or clinically significant portal hypertension, diabetes, and an LSM of ≥10 kPa, annual HCC rates were 0.46 per 100 PY (0.29-0.78), which is above the previously described threshold for cost-effectiveness for HCC surveillance. CONCLUSIONS: LSM is associated with HCC risk in MASLD. HCC surveillance should be considered in noncirrhotic MASLD with diabetes and LSM of ≥10 kPa.
引用
- John BV, Bastaich DR, Deng Y, et al. Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2025. PMID: 40810411. doi:10.1097/HEP.0000000000001498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。